NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

Post-LOE

norethindrone and ethinyl estradiol

Aurobindo Pharma

ANDAORALTABLET

Approved

Mar 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (norethindrone and ethinyl estradiol) by Aurobindo Pharma is ovulation. Approved for pregnancy in women. First approved in 2016.

Drug data last refreshed 20h ago

Mechanism of Action

ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Indications (1)

pregnancy in women

Clinical Trials (1)

NCT01953809Phase 1Withdrawn

A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women

Started Aug 2014

Infections, Bacterial

Company

Worked on NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.